ValueScreener

ValueScreener company report

MiniMed Group, Inc. (MMEDV)

NASDAQ / Healthcare / Surgical & Medical Instruments & Apparatus

Share price

17.13 USD Market dataClose of Oct 14, 2026

Market capitalisation

479.5M USD Market dataClose of Oct 14, 2026
Market data
Oct 14, 2026
Filed accounts
FY2026, filed Jun 29, 2026
Ratios computed
no recompute on record
Filed years
3, FY2024 to FY2026
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-9.2% Computed

From the FY2026 filing

Read quality

Financial strength

Debt to equity

n/a Computed

From the FY2026 filing

Why n/a

No figures have been computed for this company yet, though we hold its filings.

Read financial strength

Valuation

Price to earnings

n/m Computed

FY2026 accounts, priced at the latest close

Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

Read valuation

Cash generation

Free cash flow yield

n/a Computed

FY2026 accounts, priced at the latest close

Why n/a

No figures have been computed for this company yet, though we hold its filings.

Read cash generation

Revenue and net income, as filed

FY2024 Revenue: 2.47B USDFY2024 Net income: -112.0M USDFY2025 Revenue: 2.71B USDFY2025 Net income: -213.0M USDFY2026 Revenue: 3.10B USDFY2026 Net income: -333.0M USD
Revenue Net income3 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
No named test could be run. Which tests
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Price to earnings for MiniMed Group, Inc. in FY2026: n/a. No close is held for this fiscal year end. The price archive here is about five years deep, so older years of a price ratio are not computed.

Is it good

Return on invested capital for MiniMed Group, Inc. in FY2026: n/a. The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

Is it safe

Interest coverage for MiniMed Group, Inc. in FY2026: n/a. No interest expense is filed for this year, so coverage is not computed.

Year by year against peers
Whether MiniMed Group, Inc.'s gross margin stayed above the median of the Healthcare sector, year by year. (FY2024 to FY2026, 3 fiscal years of MiniMed Group, Inc. with a comparable figure)
What could explain it
What in MiniMed Group, Inc.'s filed statements could explain the movements. (4 readings drawn from the statement lines MiniMed Group, Inc. filed)
What to check next
What to check next on MiniMed Group, Inc., and where in its filings. (2 questions for MiniMed Group, Inc.)
In one paragraph
One paragraph on MiniMed Group, Inc.'s returns, cash, balance sheet and price. (6 of sixteen figures read for MiniMed Group, Inc.)

These are MMEDV’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research MMEDVPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2026 annual report: 10-K, filed Jun 29, 2026, accession 0001628280-26-045915.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

MiniMed Group, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Return on equity-9.2% ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Operating margin-6.1% ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Net margin-10.7% ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

MiniMed Group, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Current ratio
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Altman Z-score
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Net debt
Why n/a

The FY2026 balance sheet carries no net debt we could read.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Total assets 4.63BTotal liabilities 1.02BShareholders' equity 3.61BOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What MiniMed Group, Inc owned and owed at the end of fiscal 2026, from the balance sheet it filed (10-K, filed Jun 29, 2026, 0001628280-26-045915).

MiniMed Group, Inc: balance sheet position
Total assets4.63B FiledFY2026 10-K, filed Jun 29, 2026
Total liabilities1.02B FiledFY2026 10-K, filed Jun 29, 2026
Shareholders' equity3.61B FiledFY2026 10-K, filed Jun 29, 2026
Cash298.0M FiledFY2026 10-K, filed Jun 29, 2026
Total debtn/a FiledFY2026 10-K, filed Jun 29, 2026
Net debtn/a
Current ration/a
Debt to equityn/a
  • Debt to equity: FY2026: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Interest cover: FY2026: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

MiniMed Group, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

n/m ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
P/E on trailing twelve months
Why n/a

A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 3 for this company. Nothing is drawn rather than a line built from fewer.

n/a ComputedClose of Oct 14, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Price to sales
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Enterprise value to EBIT
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Enterprise value to EBITDA
Why n/a

No enterprise value to EBITDA is held for this company.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Price to earnings over growth
Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

n/m ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Diluted earnings per share-1.30 USD FiledFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Graham number
Why n/a

No Graham number: it needs positive filed earnings and book value per share.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915

We publish no fair value or price target of our own. Value MMEDV on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for MiniMed Group, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

MiniMed Group, Inc: valuation
Share price17.13 USD
Market capitalisation479.5M USD
Enterprise value to EBITDAn/a
Graham numbern/a
Diluted earnings per share, FY2026-1.30 USD

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 3 for this company. Nothing is drawn rather than a line built from fewer.

Companies like MiniMed Group, Inc

  1. Nuvectis Pharma, Inc. (NVCT)Market cap 477.7M USD
  2. Shattuck Labs, Inc. (STTK)Market cap 481.7M USD
  3. Evolus, Inc. (EOLS)Market cap 476.9M USD
  4. 908 Devices Inc. (MASS)Market cap 485.4M USD
  5. CytomX Therapeutics, Inc. (CTMX)Market cap 485.9M USD

Same sector (Healthcare) and size band (Small, 300M to 2B), nearest in market value. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

MiniMed Group, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Free cash flow-420.0M USD ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Dividend yield
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedClose of Oct 14, 2026 · FY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
FY2024 Free cash flow: -107.0M USDFY2024 Net income: -112.0M USDFY2025 Free cash flow: -53.0M USDFY2025 Net income: -213.0M USDFY2026 Free cash flow: -420.0M USDFY2026 Net income: -333.0M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filing

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

MiniMed Group, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2026Oct 14, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2026Oct 14, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Oct 14, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Oct 14, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Jun 29, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Oct 14, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Jun 29, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Jun 29, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Oct 14, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/mFY2026Oct 14, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2026Oct 14, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Jun 29, 2026
n/a No figures have been computed for this company yet, though we hold its filings.
n/aFY2026Jun 29, 2026
n/a No figures have been computed for this company yet, though we hold its filings.

The figures are computed from the accounts for fiscal 2026, the newest full year on file. 3 filed fiscal years on record, FY2024 to FY2026, from SEC EDGAR. Prices as of Oct 14, 2026. No recompute is on record for it. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

3 filed fiscal years, FY2024 to FY2026, read from the annual reports MiniMed Group, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

MiniMed Group, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY20263.10B-190.0M-333.0M-1.30-420.0M-6.1%-9.2%10-K, Jun 29, 20260001628280-26-045915
FY20252.71B-146.0M-213.0M-0.84-53.0M-5.4%-6.4%10-K, Jun 29, 20260001628280-26-045915
FY20242.47B-69.0M-112.0M-0.44-107.0M-2.8%n/a10-K, Jun 29, 20260001628280-26-045915
  • Revenue, compound annual growth FY2024 to FY2026: 12.1%
  • Earnings: Earnings was not positive in both 2024 and 2026, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2024 and 2026, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2024 and 2026, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

MiniMed Group, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915
Piotroski F-score
Why n/a

No figures have been computed for this company yet, though we hold its filings.

n/a ComputedFY2026 10-K, filed Jun 29, 2026, 0001628280-26-045915

The named tests

MMEDV is an active listing and we hold no computed figures for it yet, so there is nothing to measure against a criterion.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • We hold 3 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy